X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF).
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Aileron Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2023
Details:
The phase 1a clinical trial assessed ascending doses of LTI-03,, a Caveolin-1-related peptide in healthy normal volunteers. LTI-03 dose levels from 2.5 mg to 10 mg appeared to be safe and well tolerated with no reports of discontinuations or serious adverse events.
Lead Product(s): Caveolin-1-scaffolding Protein-derived Peptide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Under the terms of the agreement, Taiho will obtain the rights for the development and commercialization of LTI-01 in Japan. Lung Tx will receive an upfront payment, milestone, and royalty payments based on product sales.
Lead Product(s): LTI-01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
